Admittedly I was pleasantly surprised when the CEO said, "We continue to evaluate psychedelic medicine opportunities; the revival of these compounds has so much potential to change the lives of patients with long standing mental health conditions". Then seeing in the presentation a second psychedelic medicine trial has been largely advanced with further details to be released to market as soon as appropriate. Wow.
Just an FYI, the TGA is currently considering whether psychiatrists should be allowed to prescribe MDMA and psilocybin to treat mental illness. The TGA will announce its interim decision on February 3, and will make a final ruling on April 22. The Compass Pathways & Usona success was used in the TGA submission, of course along with other reasons justifying the reclassification of these psychedelics. If the TGA reclassifies MDMA and psilocybin, Australia would be the first country in the world to recognise these drugs as legitimate medicines.
And that's just the psychedelic arm of the business. Looking forward to all updates, especially the pre-IND meeting with FDA for IHL-675A.